Breaking News Instant updates and real-time market news.

SAGE

Sage Therapeutics

$41.14

0.26 (0.64%)

, ALKS

Alkermes

$42.37

0.07 (0.17%)

10:25
10/18/16
10/18
10:25
10/18/16
10:25

Leerink biotech analysts hold an analyst/industry conference call

Analysts discuss the recent data, controversies and catalysts for treating postpartum depression on an Analyst/Industry conference call to be held on October 18 at 11 am.

SAGE

Sage Therapeutics

$41.14

0.26 (0.64%)

ALKS

Alkermes

$42.37

0.07 (0.17%)

  • 18

    Oct

  • 06

    Nov

  • 14

    Dec

SAGE Sage Therapeutics
$41.14

0.26 (0.64%)

10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
10/04/16
LEER
10/04/16
INITIATION
Target $68
LEER
Outperform
SAGE Therapeutics reinstated with an Outperform at Leerink
Leerink analyst Paul Matteis resumed coverage of SAGE Therapeutics with an Outperform rating and $68 price target.
09/13/16
RAJA
09/13/16
INITIATION
Target $75
RAJA
Outperform
SAGE Therapeutics initiated with an Outperform at Raymond James
Raymond James analyst Christopher Raymond initiated SAGE Therapeutics with an Outperform and a $75 price target. Raymond likes the setup on SAGE shares as key validation of its unique central nervous system drug development approach nears through pivotal SAGE-547 data, expected 1H 2017. Combining this with a pipeline holding numerous unmodeled call options and a platform capable of generating novel agents in a space lacking innovation, he believes shares will move higher.
09/07/16
ROTH
09/07/16
NO CHANGE
Target $149
ROTH
Buy
Ligand has 'major catalyst' ahead, says Roth Capital
Roth Capital analyst Joseph Pantginis says Ligand (LGND) is expecting a "major catalyst" this month namely the Phase IIb sparsentan data in focal segmental glomerulosclerosis patients being developed by partner Retrophin (RTRX). In a separate note to investors, Pantginis also said that the Breakthrough Therapy Designation of SAGE Therapeutics' (SAGE) '547 for postpartum depression may expedite its development and approval for use in the clinic, noting that the company has an agreement of 3% royalty payment to Ligand for potential sales of the drug. The analyst recommends steady accumulation of Ligand's stock as he anticipates that current revenue streams from partnered products and the broad "in development" portfolio are poised to drive significant growth in the near and longer term. He reiterates a Buy rating and $149 price target on Ligand's shares.
ALKS Alkermes
$42.37

0.07 (0.17%)

10/18/16
JEFF
10/18/16
NO CHANGE
JEFF
Jefferies sees 'attractive buying opportunities' in Biotech
The Jefferies Biotechnology team sees "attractive buying opportunities" amidst the pre-election weakness. While volatility will likely continue into the election, valuation multiples are near-historic lows and policy concerns, while valid, are likely overstated, the analysts tell investors in a research note. They recommend using the weakness to buy select names ahead of a potential improvement in sentiment. Jefferies likes Gilead (GILD) and Celgene (CELG) among large-caps, The Medicines Co. (MDCO), Alkermes (ALKS) and Vertex (VRTX) among mid-caps, and Alder Biopharmaceuticals (ALDR), Cempra (CEMP), Ultragenyx (RARE) and Immunomedics (IMMU) among small-caps.
10/04/16
LEER
10/04/16
INITIATION
Target $57
LEER
Outperform
Alkermes reinstated with an Outperform at Leerink
Leerink analyst Paul Matteis resumed coverage of Alkermes with an Outperform rating and $57 price target.
09/27/16
JEFF
09/27/16
NO CHANGE
Target $62
JEFF
Buy
Alkermes sees significant room for Vivitrol upside, says Jefferies
Alkermes yesterday at its Vivitrol-focused event highlighted that the opioid treatment is still in the early stages of growth, Jefferies analyst Biren Amin tells investors in a research note. The company estimates that Vivitrol is currently capturing only 2% average market share and believes room for upside is significant, the analyst writes. He keeps a Buy rating on Alkermes with a $62 price target.
09/27/16
SBSH
09/27/16
NO CHANGE
Target $53
SBSH
Neutral
Alkermes price target raised to $53 from $44 at Citi
Citi analyst Liav Abraham raised her price target for Alkermes to $53 after the company hosted an investor event to overview the various aspects of Vivitrol. Alkermes' execution on a "unique commercial model," which targets the differing opioid addiction population needs on a state-by-state basis, is likely to drive robust volume growth going forward, particularly in the Medicaid patient population, Abraham tells investors in a research note. The analyst raised her estimates for Vivitrol but remains cautious on the FORWARD-5 data for ALKS 5461 due out in Q4. As such, Abraham keeps a Neutral rating on Alkermes.

TODAY'S FREE FLY STORIES

BX

Blackstone

$35.81

0.42 (1.19%)

12:05
01/16/18
01/16
12:05
01/16/18
12:05
Options
Blackstone call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

ICBK

County Bancorp

$30.16

0.38 (1.28%)

, MTW

Manitowoc

$40.09

0.73 (1.85%)

12:04
01/16/18
01/16
12:04
01/16/18
12:04
Hot Stocks
ICB to purchase Manitowoc Company headquarters »

Investors Community Bank,…

ICBK

County Bancorp

$30.16

0.38 (1.28%)

MTW

Manitowoc

$40.09

0.73 (1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$31.78

0.405 (1.29%)

12:02
01/16/18
01/16
12:02
01/16/18
12:02
Hot Stocks
Roche launches CE-marked VENTANA MMR IHC Panel »

Roche announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 23

    Feb

NSRGY

Nestle

$85.10

0.58 (0.69%)

12:02
01/16/18
01/16
12:02
01/16/18
12:02
Hot Stocks
Nestle agrees to sell U.S. confectionery business to Ferrero »

Nestle announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$54.16

-0.38 (-0.70%)

12:00
01/16/18
01/16
12:00
01/16/18
12:00
Periodicals
Hess to cut hundreds of jobs as it battles activist shareholder, Reuters says »

Hess plans to lay off…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CECE

CECO Environmental

$5.22

-0.07 (-1.32%)

12:00
01/16/18
01/16
12:00
01/16/18
12:00
Hot Stocks
CECO Environmental reports award of 'large contract' to energy business »

CECO Environmental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 17

    Jan

INFO

IHS Markit

$47.85

0.39 (0.82%)

11:55
01/16/18
01/16
11:55
01/16/18
11:55
Conference/Events
IHS Markit management to meet with RBC Capital »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 16

    Jan

GSK

GlaxoSmithKline

$37.74

0.24 (0.64%)

11:54
01/16/18
01/16
11:54
01/16/18
11:54
Upgrade
GlaxoSmithKline rating change  »

GlaxoSmithKline upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

  • 25

    Mar

GSK

GlaxoSmithKline

$37.76

0.2646 (0.71%)

11:51
01/16/18
01/16
11:51
01/16/18
11:51
Upgrade
GlaxoSmithKline rating change  »

GlaxoSmithKline upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

  • 25

    Mar

SPY

SPDR S&P 500 ETF Trust

$278.99

1.07 (0.39%)

, SPX

S&P 500

11:50
01/16/18
01/16
11:50
01/16/18
11:50
Periodicals
Steve Bannon subpoenaed before grand jury by Mueller, NY Time says »

Special counsel Robert…

SPY

SPDR S&P 500 ETF Trust

$278.99

1.07 (0.39%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$11.67

0.1978 (1.72%)

11:50
01/16/18
01/16
11:50
01/16/18
11:50
Options
Large spreads in Petrobras as shares reach 52-week highs »

Large spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$62.38

3.72 (6.34%)

11:45
01/16/18
01/16
11:45
01/16/18
11:45
Options
Merck call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 02

    Feb

  • 08

    Feb

  • 25

    Mar

  • 03

    Apr

  • 23

    Oct

11:45
01/16/18
01/16
11:45
01/16/18
11:45
General news
Treasury's $90 B bill auction were mixed, with the 3-month outperforming »

Treasury's $90 B…

TTMI

TTM Technologies

$17.39

0.59 (3.51%)

11:45
01/16/18
01/16
11:45
01/16/18
11:45
Conference/Events
TTM Technologies management to meet with SunTrust »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 17

    Jan

11:40
01/16/18
01/16
11:40
01/16/18
11:40
General news
U.S. VIX equity volatility is up nearly 10% »

U.S. VIX equity…

LPI

Laredo Petroleum

$11.09

0.015 (0.14%)

11:36
01/16/18
01/16
11:36
01/16/18
11:36
Initiation
Laredo Petroleum initiated  »

Laredo Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:35
01/16/18
01/16
11:35
01/16/18
11:35
General news
6-Month Bill Auction Total Amount data reported »

6-Month Bill Auction…

11:34
01/16/18
01/16
11:34
01/16/18
11:34
General news
3-Month Bill Auction Total Amount data reported »

3-Month Bill Auction…

EVRI

Everi Holdings

$7.85

-0.09 (-1.13%)

, SGMS

Scientific Games

11:31
01/16/18
01/16
11:31
01/16/18
11:31
Hot Stocks
Everi Holdings names Harper Ko EVP, Chief Legal Officer - General Counsel »

Everi Holdings (EVRI)…

EVRI

Everi Holdings

$7.85

-0.09 (-1.13%)

SGMS

Scientific Games

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$17.79

0.03 (0.17%)

11:30
01/16/18
01/16
11:30
01/16/18
11:30
Options
Put buyers in Gamestop as shares attempt to stabilize »

Put buyers in Gamestop as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOG

Extraction Oil & Gas

$14.16

-0.13 (-0.91%)

11:28
01/16/18
01/16
11:28
01/16/18
11:28
Conference/Events
Extraction Oil & Gas management to meet with SunTrust »

Field trip to company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

  • 28

    Feb

  • 15

    May

11:27
01/16/18
01/16
11:27
01/16/18
11:27
Conference/Events
Cowen healthcare policy analyst holds an analyst/industry conference call »

Healthcare Policy Analyst…

11:25
01/16/18
01/16
11:25
01/16/18
11:25
Conference/Events
Wolfe Research airlines analyst hosts a luncheon »

Airlines Analyst Keay…

C

Citi

$77.46

0.615 (0.80%)

11:22
01/16/18
01/16
11:22
01/16/18
11:22
Hot Stocks
Breaking Hot Stocks news story on Citi »

Citi CEO Corbat says open…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

TTMI

TTM Technologies

$17.39

0.59 (3.51%)

11:21
01/16/18
01/16
11:21
01/16/18
11:21
Conference/Events
TTM Technologies management to meet with SunTrust »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 17

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.